Form 4 Filing for BridgeBio Pharma, Inc. (BBIO)

This filing details stock transactions by Valantine Hannah, a director at BridgeBio Pharma, Inc. On June 22, 2026, Hannah acquired 3,990 restricted stock units (RSUs) with a reported value of $0, vesting on June 22, 2027. The same day, Hannah acquired 2,808 shares of common stock at $41.73 per share and disposed of 2,808 shares at $68 per share, a transaction effected under a Rule 10b5-1 sales plan. Additionally, options to purchase 5,277 shares were granted at $0, with vesting conditions mentioned. Another option transaction involved the disposal of 2,808 shares at $0, with vesting conditions detailed. On June 23, 2026, 2,196 shares were disposed of at $68.57 per share, also under a Rule 10b5-1 plan. The filing also notes indirect ownership of 398 shares by a spouse.